Spinnaker Trust Sells 155 Shares of Danaher Co. (NYSE:DHR)

Spinnaker Trust lowered its stake in Danaher Co. (NYSE:DHR) by 3.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,254 shares of the conglomerate’s stock after selling 155 shares during the period. Spinnaker Trust’s holdings in Danaher were worth $1,183,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of DHR. Vanguard Group Inc. boosted its stake in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Legal & General Group Plc raised its holdings in Danaher by 2.4% during the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock valued at $1,490,112,000 after buying an additional 139,989 shares during the last quarter. Capital Research Global Investors boosted its position in Danaher by 1.0% during the 1st quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock valued at $1,279,932,000 after buying an additional 52,679 shares during the period. Dimensional Fund Advisors LP grew its holdings in Danaher by 2.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock worth $849,195,000 after acquiring an additional 85,081 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DHR has been the subject of a number of analyst reports. Stephens reiterated an “overweight” rating and set a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research report on Thursday, October 31st. The Goldman Sachs Group boosted their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Royal Bank of Canada cut their price target on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, Bank of America boosted their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Six investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by company insiders.

Danaher Stock Performance

NYSE DHR traded down $3.47 on Wednesday, reaching $246.60. 730,389 shares of the stock were exchanged, compared to its average volume of 2,733,946. The company’s 50-day simple moving average is $266.16 and its two-hundred day simple moving average is $260.84. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The firm has a market capitalization of $178.11 billion, a PE ratio of 47.74, a PEG ratio of 4.55 and a beta of 0.85. Danaher Co. has a one year low of $192.35 and a one year high of $281.70.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. During the same quarter in the prior year, the firm posted $2.02 EPS. Danaher’s quarterly revenue was up 3.1% compared to the same quarter last year. Analysts expect that Danaher Co. will post 7.51 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s payout ratio is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.